During and after an exacerbation, mental recovery involves taking care of both your physical and mental health. Resting, ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb.

Objective: To investigate the efficacy and tolerability of high-dose N-acetylcysteine (NAC) in the treatment of patients with exacerbations of chronic obstructive pulmonary disease (COPD).

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

In a world where respiratory issues are increasingly common, finding practical solutions can be daunting. Breathe Drops ...

Apogee begins patient dosing in Part B of phase 2 APEX trial of APG777 to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 4, 2025, 18:00 Hrs [IST] Apog ...

Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine ...

Nearly four million patients with asthma or chronic obstructive pulmonary disease (COPD ... dosing regimens given with placebo. The group taking prednisolone alone had a 74% treatment failure ...

Subhro Mallik highlights the transformative role of AI and predictive analytics in chronic disease management, offering early ...

Breathing is essential for life, yet for many individuals suffering from chronic respiratory issues such as asthma and COPD, ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...

Apogee Therapeutics, Inc. (NASDAQ: APGE) has announced the dosing of the first patient in the part B portion of the phase 2 ...